Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Bls 1 frá 16 niðurstöður
Medical uses of allosteric hemoglobin modifier compounds in patient care
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
DESCRIPTION
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to using a family of compounds to adjust the allosteric equilibrium of hemoglobin toward a low oxygen affinity state. Moreover, the invention includes several new compounds and contemplates
Systems, devices and methods for the treatment of neurological disorders and conditions
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
Systems, devices and methods for the treatment of neurological disorders and conditions
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
Systems, devices and methods for the treatment of neurological disorders and conditions
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
This application is also related to the following copending applications: U.S. application Ser. No. 12/898,685, entitled "Extracranial Implantable Devices, Systems and Methods for Treatment of Neuropsychiatric Disorders," filed on even date herewith with U.S. application Ser. No. 12/898,686,
Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-dione type. The fused ring system is substituted at the a- or b-position by amino acid derivatives. The compounds are active as excitatory amino
Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a- or b-position by amino acid derivatives. The compounds are active as excitatory amino
Substituted quinoxaline-2-ones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The
Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
Azolylacryloyl derivatives as therapeutic agents for sickle cell disease
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
Field of the Invention
The invention generally relates to agents with hypoxic properties for treating disease. In particular, the invention provides azolylacryloyl derivatives with hypoxic properties that are suitable for treating sickle cell disease, and
Phenylalkanoylamine derivatives, process for preparing the same, and usage of the same
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
This invention relates to novel phenylalkanoylamine derivatives which are useful as medicines for treating or preventing cerebral circulation disorder, cerebral metabolism disorder, and memory disturbance, and to a process for preparing the same.
DESCRIPTION OF THE BACKGROUND
Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The invention relates to the use of triazolones as pharmaceutical compositions, particularly pharmaceutical compositions with a neuroprotective activity, as well as new triazolones and processes for preparing them.
Triazolones are known from the prior art and are disclosed, for example, by published
Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The
Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active
Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
